Literature DB >> 34936740

Multicomponent Strategy with Decentralized Molecular Testing for Tuberculosis.

Adithya Cattamanchi1, Tania F Reza1, Talemwa Nalugwa1, Katherine Adams1, Mariam Nantale1, Denis Oyuku1, Sarah Nabwire1, Diana Babirye1, Stavia Turyahabwe1, Austin Tucker1, Hojoon Sohn1, Olivia Ferguson1, Ryan Thompson1, Priya B Shete1, Margaret A Handley1, Sara Ackerman1, Moses Joloba1, David A J Moore1, J Lucian Davis1, David W Dowdy1, Katherine Fielding1, Achilles Katamba1.   

Abstract

BACKGROUND: Effective strategies are needed to facilitate the prompt diagnosis and treatment of tuberculosis in countries with a high burden of the disease.
METHODS: We conducted a cluster-randomized trial in which Ugandan community health centers were assigned to a multicomponent diagnostic strategy (on-site molecular testing for tuberculosis, guided restructuring of clinic workflows, and monthly feedback of quality metrics) or routine care (on-site sputum-smear microscopy and referral-based molecular testing). The primary outcome was the number of adults treated for confirmed tuberculosis within 14 days after presenting to the health center for evaluation during the 16-month intervention period. Secondary outcomes included completion of tuberculosis testing, same-day diagnosis, and same-day treatment. Outcomes were also assessed on the basis of proportions.
RESULTS: A total of 20 health centers underwent randomization, with 10 assigned to each group. Of 10,644 eligible adults (median age, 40 years) whose data were evaluated, 60.1% were women and 43.8% had human immunodeficiency virus infection. The intervention strategy led to a greater number of patients being treated for confirmed tuberculosis within 14 days after presentation (342 patients across 10 intervention health centers vs. 220 across 10 control health centers; adjusted rate ratio, 1.56; 95% confidence interval [CI], 1.21 to 2.01). More patients at intervention centers than at control centers completed tuberculosis testing (adjusted rate ratio, 1.85; 95% CI, 1.21 to 2.82), received a same-day diagnosis (adjusted rate ratio, 1.89; 95% CI, 1.39 to 2.56), and received same-day treatment for confirmed tuberculosis (adjusted rate ratio, 2.38; 95% CI, 1.57 to 3.61). Among 706 patients with confirmed tuberculosis, a higher proportion in the intervention group than in the control group were treated on the same day (adjusted rate ratio, 2.29; 95% CI, 1.23 to 4.25) or within 14 days after presentation (adjusted rate ratio, 1.22; 95% CI, 1.06 to 1.40).
CONCLUSIONS: A multicomponent diagnostic strategy that included on-site molecular testing plus implementation supports to address barriers to delivery of high-quality tuberculosis evaluation services led to greater numbers of patients being tested, receiving a diagnosis, and being treated for confirmed tuberculosis. (Funded by the National Heart, Lung, and Blood Institute; XPEL-TB ClinicalTrials.gov number, NCT03044158.).
Copyright © 2021 Massachusetts Medical Society.

Entities:  

Mesh:

Year:  2021        PMID: 34936740      PMCID: PMC9212879          DOI: 10.1056/NEJMoa2105470

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   176.079


  23 in total

1.  The arrival of a true point-of-care molecular assay-ready for global implementation?

Authors:  Paul K Drain; Nigel J Garrett
Journal:  Lancet Glob Health       Date:  2015-11       Impact factor: 26.763

2.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

3.  Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa).

Authors:  Lucky G Ngwira; Elizabeth L Corbett; McEwen Khundi; Grace L Barnes; Austin Nkhoma; Michael Murowa; Silvia Cohn; Lawrence H Moulton; Richard E Chaisson; David W Dowdy
Journal:  Clin Infect Dis       Date:  2019-03-19       Impact factor: 9.079

4.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 5.  Pre-treatment loss to follow-up in tuberculosis patients in low- and lower-middle-income countries and high-burden countries: a systematic review and meta-analysis.

Authors:  Peter MacPherson; Rein M G J Houben; Judith R Glynn; Elizabeth L Corbett; Katharina Kranzer
Journal:  Bull World Health Organ       Date:  2013-11-22       Impact factor: 9.408

6.  Cost of tuberculosis diagnosis and treatment from the patient perspective in Lusaka, Zambia.

Authors:  A Aspler; D Menzies; O Oxlade; J Banda; L Mwenge; P Godfrey-Faussett; H Ayles
Journal:  Int J Tuberc Lung Dis       Date:  2008-08       Impact factor: 2.373

7.  Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial.

Authors:  Helen S Cox; Slindile Mbhele; Neisha Mohess; Andrew Whitelaw; Odelia Muller; Widaad Zemanay; Francesca Little; Virginia Azevedo; John Simpson; Catharina C Boehme; Mark P Nicol
Journal:  PLoS Med       Date:  2014-11-25       Impact factor: 11.069

Review 8.  Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Authors:  Heidi Albert; Ruvandhi R Nathavitharana; Chris Isaacs; Madhukar Pai; Claudia M Denkinger; Catharina C Boehme
Journal:  Eur Respir J       Date:  2016-07-13       Impact factor: 16.671

9.  Missed Opportunities for TB Investigation in Primary Care Clinics in South Africa: Experience from the XTEND Trial.

Authors:  Violet N Chihota; Sibuse Ginindza; Kerrigan McCarthy; Alison D Grant; Gavin Churchyard; Katherine Fielding
Journal:  PLoS One       Date:  2015-09-18       Impact factor: 3.240

10.  Surrogate endpoints in global health research: still searching for killer apps and silver bullets?

Authors:  Madhukar Pai; Samuel G Schumacher; Seye Abimbola
Journal:  BMJ Glob Health       Date:  2018-03-08
View more
  2 in total

1.  Guillain-Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report.

Authors:  Fabio Giuseppe Masuccio; Cristoforo Comi; Claudio Solaro
Journal:  Acta Neurol Belg       Date:  2021-11-12       Impact factor: 2.471

Review 2.  Diagnosing Tuberculosis: What Do New Technologies Allow Us to (Not) Do?

Authors:  Shima M Abdulgader; Anna O Okunola; Gcobisa Ndlangalavu; Byron W P Reeve; Brian W Allwood; Coenraad F N Koegelenberg; Rob M Warren; Grant Theron
Journal:  Respiration       Date:  2022-06-27       Impact factor: 3.966

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.